1
|
Xu AL, Suresh KV, Gomez JA, Emans JB, Larson AN, Cahill PJ, Andras LM, White KK, Miller DJ, Murphy JS, Groves ML, Belzberg AJ, Hwang SW, Rosser TL, Staedtke V, Ullrich NJ, Sato AA, Blakeley JO, Schorry EK, Gross AM, Redding GJ, Sponseller PD. Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy. J Pediatr Orthop 2023; 43:e531-e537. [PMID: 37253707 PMCID: PMC10523927 DOI: 10.1097/bpo.0000000000002431] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Spinal conditions, such as scoliosis and spinal tumors, are prevalent in neurofibromatosis type 1 (NF1). Despite the recognized importance of their early detection and treatment, there remain knowledge gaps in how to approach these manifestations. The purpose of this study was to utilize the experience of a multidisciplinary committee of experts to establish consensus-based best practice guidelines (BPGs) for spinal screening and surveillance, surgical intervention, and medical therapy in pediatric patients with NF1. METHODS Using the results of a prior systematic review, 10 key questions that required further assessment were first identified. A committee of 20 experts across medical specialties was then chosen based on their clinical experience with spinal deformity and tumors in NF1. These were 9 orthopaedic surgeons, 4 neuro-oncologists/oncologists, 3 neurosurgeons, 2 neurologists, 1 pulmonologist, and 1 clinical geneticist. An initial online survey on current practices and opinions was conducted, followed by 2 additional surveys via a formal consensus-based modified Delphi method. The final survey involved voting on agreement or disagreement with 35 recommendations. Items reaching consensus (≥70% agreement or disagreement) were included in the final BPGs. RESULTS Consensus was reached for 30 total recommendations on the management of spinal deformity and tumors in NF1. These were 11 recommendations on screening and surveillance, 16 on surgical intervention, and 3 on medical therapy. Five recommendations did not achieve consensus and were excluded from the BPGs. CONCLUSION We present a set of consensus-based BPGs comprised of 30 recommendations for spinal screening and surveillance, surgical intervention, and medical therapy in pediatric NF1.
Collapse
Affiliation(s)
- Amy L. Xu
- Dept. of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD
| | - Krishna V. Suresh
- Dept. of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD
| | - Jaime A. Gomez
- Dept. of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY
| | - John B. Emans
- Dept. of Orthopaedic Surgery, Boston Children’s Hospital, Boston, MA
| | | | - Patrick J. Cahill
- Dept. of Orthopaedic Surgery, Children’s Hospital of Philadelphia, Philadelphia, PA
| | - Lindsay M. Andras
- Dept. of Orthopaedic Surgery, Children’s Hospital Los Angeles, Los Angeles, CA
| | - Klane K. White
- Dept. of Orthopaedic Surgery, Children’s Hospital Colorado, Aurora, CO
| | - Daniel J. Miller
- Dept. of Orthopaedic Surgery, Gillette Children’s Hospital, St. Paul, MN
| | - Joshua S. Murphy
- Dept. of Orthopaedic Surgery, Children’s Healthcare of Atlanta, Atlanta, GA
| | - Mari L. Groves
- Dept. of Neurosurgery, The Johns Hopkins Hospital, Baltimore, MD
| | | | - Steven W. Hwang
- Dept. of Neurosurgery, Shriners Hospitals for Children, Philadelphia, PA
| | - Tena L. Rosser
- Dept. of Neurology, Children’s Hospital Los Angeles, Los Angeles, CA
| | - Verena Staedtke
- Dept. of Neurology, The Johns Hopkins Hospital, Baltimore, MD
| | | | - Aimee A. Sato
- Dept. of Neurology, Seattle Children’s Hospital, Seattle, WA
| | | | | | - Andrea M. Gross
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
| | - Gregory J. Redding
- Dept. of Pulmonology and Sleep Medicine, Seattle Children’s Hospital, Seattle, WA
| | | | | |
Collapse
|
2
|
Shin DS, Choi WY, Cheon JS, Choi MH. Accidental diagnosis of a giant malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1 in the back area: a case report. ARCHIVES OF AESTHETIC PLASTIC SURGERY 2022. [DOI: 10.14730/aaps.2021.00290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are rare and aggressive soft tissue sarcomas of neural origin. Approximately 50% of MPNSTs are associated with neurofibromatosis type 1 (NF1), a neurocutaneous condition characterized by skin discoloration. MPNSTs occur in approximately 4% of patients with NF1. Malignancy should be suspected when a large mass consistent with a neurofibroma is observed with heterogeneity on a radiologic examination. In our case, immunohistochemistry revealed the presence of antigens for both the tumor protein p53 and the proliferation marker Ki-67 (MKI67). In particular, MKI67 positivity helped to differentiate MPNST from neurofibroma. Complete surgical resection is the standard treatment. After surgery, radiation therapy is typically administered to the resection area to reduce the likelihood of recurrence. Following treatment, patients should undergo regular clinical follow-up using a combination of magnetic resonance imaging, computed tomography, and bone scanning for several years to monitor them for possible metastasis.
Collapse
|
3
|
Morris SM, Gupta A, Kim S, Foraker RE, Gutmann DH, Payne PRO. Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1. Neurol Clin Pract 2022; 11:497-505. [PMID: 34987881 PMCID: PMC8723929 DOI: 10.1212/cpj.0000000000001089] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 02/25/2021] [Indexed: 12/23/2022]
Abstract
Objective To perform a longitudinal analysis of clinical features associated with
neurofibromatosis type 1 (NF1) based on demographic and clinical
characteristics and to apply a machine learning strategy to determine
feasibility of developing exploratory predictive models of optic pathway
glioma (OPG) and attention-deficit/hyperactivity disorder (ADHD) in a
pediatric NF1 cohort. Methods Using NF1 as a model system, we perform retrospective data analyses using a
manually curated NF1 clinical registry and electronic health record (EHR)
information and develop machine learning models. Data for 798 individuals
were available, with 578 comprising the pediatric cohort used for
analysis. Results Males and females were evenly represented in the cohort. White children were
more likely to develop OPG (odds ratio [OR]: 2.11, 95% confidence interval
[CI]: 1.11–4.00, p = 0.02) relative to their
non-White peers. Median age at diagnosis of OPG was 6.5 years
(1.7–17.0), irrespective of sex. Males were more likely than females
to have a diagnosis of ADHD (OR: 1.90, 95% CI: 1.33–2.70,
p < 0.001), and earlier diagnosis in males
relative to females was observed. The gradient boosting classification model
predicted diagnosis of ADHD with an area under the receiver operator
characteristic (AUROC) of 0.74 and predicted diagnosis of OPG with an AUROC
of 0.82. Conclusions Using readily available clinical and EHR data, we successfully recapitulated
several important and clinically relevant patterns in NF1 semiology
specifically based on demographic and clinical characteristics. Naive
machine learning techniques can be potentially used to develop and validate
predictive phenotype complexes applicable to risk stratification and disease
management in NF1.
Collapse
Affiliation(s)
- Stephanie M Morris
- Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO
| | - Aditi Gupta
- Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO
| | - Seunghwan Kim
- Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO
| | - Randi E Foraker
- Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO
| | - David H Gutmann
- Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO
| | - Philip R O Payne
- Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO
| |
Collapse
|
4
|
Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment. Pain 2020; 160:1007-1018. [PMID: 31009417 DOI: 10.1097/j.pain.0000000000001486] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Neurofibromatosis type 1 (NF1) is the most common of a group of rare diseases known by the term, "Neurofibromatosis," affecting 1 in 3000 to 4000 people. NF1 patients present with, among other disease complications, café au lait patches, skin fold freckling, Lisch nodules, orthopedic complications, cutaneous neurofibromas, malignant peripheral nerve sheath tumors, cognitive impairment, and chronic pain. Although NF1 patients inevitably express pain as a debilitating symptom of the disease, not much is known about its manifestation in the NF1 disease, with most current information coming from sporadic case reports. Although these reports indicate the existence of pain, the molecular signaling underlying this symptom remains underexplored, and thus, we include a synopsis of the literature surrounding NF1 pain studies in 3 animal models: mouse, rat, and miniswine. We also highlight unexplored areas of NF1 pain research. As therapy for NF1 pain remains in various clinical and preclinical stages, we present current treatments available for patients and highlight the importance of future therapeutic development. Equally important, NF1 pain is accompanied by psychological complications in comorbidities with sleep, gastrointestinal complications, and overall quality of life, lending to the importance of investigation into this understudied phenomenon of NF1. In this review, we dissect the presence of pain in NF1 in terms of psychological implication, anatomical presence, and discuss mechanisms underlying the onset and potentiation of NF1 pain to evaluate current therapies and propose implications for treatment of this severely understudied, but prevalent symptom of this rare disease.
Collapse
|
5
|
Guedes F, Brown RS, Torrão-Junior FJL, Barbosa DAN, Ravanini GDAG, Amorim RMP. Pediatric peripheral nerve tumors: clinical and surgical aspects. Childs Nerv Syst 2019; 35:2289-2297. [PMID: 31346736 DOI: 10.1007/s00381-019-04306-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Accepted: 07/10/2019] [Indexed: 02/07/2023]
Abstract
PURPOSE Pediatric peripheral nerve tumors (PNTs) are rare. Most are related to neurofibromatosis type 1 (NF1) with the potential for malignancy. An ongoing debate occurs about the best approach to such patients. This study describes a cohort of pediatric patients with PNTs and discusses clinical characteristics and surgical treatment. METHODS We retrospectively reviewed the charts of seven pediatric patients with eight PNTs surgically treated from 2007 to 2018. Information concerning patient demographics, clinical presentation, PNTs characteristics, treatment choice, and outcome were recorded. RESULTS All children presented with intense pain and a palpable mass. Three of the eight tumors were associated with a neurological deficit. Among the four patients with NF1, two had a neurofibroma and two a malignant peripheral nerve sheath tumor (MPNST). Histologically, three of the lesions were a benign peripheral nerve sheath tumor (BPNST), three a MPNST, and one each a desmoid tumor and Ewing's sarcoma. Two of the eight tumors underwent partial tumor excision and six gross total excisions. CONCLUSIONS Intense pain at rest, day, and/or night, preventing normal activities; a palpable, hard, immobile mass; an intense Tinel's sign related to the lump; clinical evidence of NF1; and high-speed growth of a tumor in the trajectory of the nerve or plexus should alert the clinician to the potential for malignancy. Preoperative biopsy is not indicated when clinical and imaging findings suggest a benign tumor. The surgical management of PNTs must be to achieve total resection, including wide margins with malignant tumors, though this is not always possible.
Collapse
Affiliation(s)
- Fernando Guedes
- Department of Surgery, Division of Neurosurgery, Gaffrée e Guinle University Hospital, School of Medicine, Federal University of Rio de Janeiro State (UNIRIO), 775 Mariz e Barros Street, Rio de Janeiro, RJ, Brazil
| | - Rosana Siqueira Brown
- Department of Surgery, Division of Neurosurgery, Gaffrée e Guinle University Hospital, School of Medicine, Federal University of Rio de Janeiro State (UNIRIO), 775 Mariz e Barros Street, Rio de Janeiro, RJ, Brazil.
| | - Francisco José Lourenço Torrão-Junior
- Department of Surgery, Division of Neurosurgery, Gaffrée e Guinle University Hospital, School of Medicine, Federal University of Rio de Janeiro State (UNIRIO), 775 Mariz e Barros Street, Rio de Janeiro, RJ, Brazil
| | - Daniel A N Barbosa
- Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA
| | - Guilherme de Andrade Gagheggi Ravanini
- Department of Surgery, Division of Surgical Oncology, Gaffrée e Guinle University Hospital, School of Medicine, Federal University of Rio de Janeiro State (UNIRIO), 775 Mariz e Barros Street, Rio de Janeiro, RJ, Brazil
| | - Rogério Martin Pires Amorim
- Department of Surgery, Division of Neurosurgery, Gaffrée e Guinle University Hospital, School of Medicine, Federal University of Rio de Janeiro State (UNIRIO), 775 Mariz e Barros Street, Rio de Janeiro, RJ, Brazil
| |
Collapse
|
6
|
Zhang L, Sun F, Li H, Du J, Zhao L. Neurofibromatosis type I with malignant peripheral nerve sheath tumors in the upper arm: A case report. Medicine (Baltimore) 2019; 98:e15017. [PMID: 30921223 PMCID: PMC6456125 DOI: 10.1097/md.0000000000015017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
RATIONALE Malignant peripheral nerve sheath tumor occurring in the context of neurofibromatosis type I (NF1) is relatively rare. Herein, we report a case of NF1 with malignant peripheral nerve sheath tumor in the upper arm. PATIENT CONCERNS A 24-year-old man presented with a mass in the medial part of the left upper arm that had been present for more than 20 years. In the previous 1 year prior to admission, the mass had grown significantly. Physical examination showed cafe-au-lait spots of variable sizes throughout the body and multiple masses in the medial part of the left upper arm. Three months later after the resection of the masses, the patient was readmitted to our department due to tumor recurrence. Two months after the extended resection, in situ recurrence of the tumor was noted again. Four months after the operation and the administration of radiotherapy, a mass was found in the outside of the left upper arm. DIAGNOSIS Immunohistochemical staining showed the masses were positivity for vimentin, CD34, and S100; the tumor cells were negative for PGP9.5, CD57, EMA, and SMA. The Ki-67 labeling index was approximately 40%. A diagnosis of malignant peripheral nerve sheath tumor was made. INTERVENTIONS Surgical resection was performed for both the primary tumors and the 2 subsequent recurrence tumors. The patient underwent radiotherapy with 60 Gy in 30 fractions after the third operation. Four months after the administration of radiotherapy, the patient underwent tumorectomy of a mass in the outside of the left upper arm. OUTCOMES During the 4-month follow-up after the fourth operation, the patient's condition was stable. LESSONS Malignant peripheral nerve sheath tumor in NF1 is an exceedingly rare entity that poses a great diagnostic challenge. High-frequency ultrasound can support the diagnosis.
Collapse
|
7
|
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. Case Rep Pathol 2017; 2017:7542825. [PMID: 29138703 PMCID: PMC5613689 DOI: 10.1155/2017/7542825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 07/26/2017] [Indexed: 11/25/2022] Open
Abstract
Benign and malignant tumors are common in the setting of neurofibromatosis type 1 (NF1). Malignant peripheral nerve sheath tumor (MPNST) and angiosarcoma are rare tumors in children and adolescents and mostly occur in young patients in relation to NF1. Both histological types can be present in the same tumor mass in patients with NF1. We present a case of 12.5-year-old girl with NF1 who first presented with MPNST of the right inguinal region and 1.5 years later with unrelated angiosarcoma of the scalp.
Collapse
|
8
|
Ugwu JO, Onwukamuche ME, Ekwunife HO, C Emejulu JK, Modekwe V, Osuigwe OA. A Case of Retroperitoneal Malignant Triton Tumor in a Nigerian Boy. Niger J Surg 2017; 23:141-144. [PMID: 29089742 PMCID: PMC5649432 DOI: 10.4103/njs.njs_57_16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Malignant peripheral nerve sheath tumor is a rare tumor occurring in 5%–10% of all malignant soft tissues sarcomas and triton tumor arising from neurofibromatosis type 1 (NF-1) is even rarer with associated high rate of mortality. No case of triton tumor has been reported in Nigeria to the best of our knowledge. We seek to report a case of lately detected retroperitoneal triton tumor presenting in a 12-year-old Nigerian child who was brought with bilateral lower limb weaknesses, weight loss, and a right lumbar mass. There were multiple café au lait spots on the body. Abdominal computerized tomographic scan revealed a huge right retroperitoneal mass crossing the midline, compressing adjacent structures with multilevel intraspinal extensions. Core needle biopsy performed and both histology and immunohistochemical studies confirmed the diagnosis, but patient demised in the course of care. The aim is to heighten suspicion of this extremely very rare malignant tumor in children with NF-1.
Collapse
Affiliation(s)
- Jideofor Okechukwu Ugwu
- Department of Surgery, Paedaitric Surgery Unit, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| | | | - Hyginus O Ekwunife
- Department of Surgery, Paedaitric Surgery Unit, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| | - Jude Kennedy C Emejulu
- Department of Surgery, Division of Neurosurgery, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| | - Victor Modekwe
- Department of Surgery, Paedaitric Surgery Unit, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| | - Osuigwe An Osuigwe
- Department of Surgery, Paedaitric Surgery Unit, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| |
Collapse
|
9
|
Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A 2017; 173:1714-1721. [PMID: 28436162 DOI: 10.1002/ajmg.a.38239] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 02/22/2017] [Indexed: 01/16/2023]
Abstract
The Annual Children's Tumor Foundation International Neurofibromatosis Meeting is the premier venue for connecting discovery, translational and clinical scientists who are focused on neurofibromatosis types 1 and 2 (NF1 and NF2) and schwannomatosis (SWN). The meeting also features rare tumors such as glioma, meningioma, sarcoma, and neuroblastoma that occur both within these syndromes and spontaneously; associated with somatic mutations in NF1, NF2, and SWN. The meeting addresses both state of the field for current clinical care as well as emerging preclinical models fueling discovery of new therapeutic targets and discovery science initiatives investigating mechanisms of tumorigenesis. Importantly, this conference is a forum for presenting work in progress and bringing together all stakeholders in the scientific community. A highlight of the conference was the involvement of scientists from the pharmaceutical industry who presented growing efforts for rare disease therapeutic development in general and specifically, in pediatric patients with rare tumor syndromes. Another highlight was the focus on new investigators who presented new data about biomarker discovery, tumor pathogenesis, and diagnostic tools for NF1, NF2, and SWN. This report summarizes the themes of the meeting and a synthesis of the scientific discoveries presented at the conference in order to make the larger research community aware of progress in the neurofibromatoses.
Collapse
Affiliation(s)
| | | | | | - Wade Clapp
- Indiana University, Indianapolis, Indiana
| | - Rosalie Ferner
- Guy's Hospital and St. Thomas' Hospital, London, United Kingdom
| | | | | | - David H Gutmann
- Washington University School of Medicine, St. Louis, Missouri
| | | | | | - Eric Legius
- Center for Human Genetics-University Hospital, Leuven, Belgium
| | - Alison C Lloyd
- MRC Laboratory for Molecular Cell Biology, University College, London, United Kingdom
| | - Roger J Packer
- Children's National Medical Center, Washington, District of Columbia
| | | | | | | | - Nicole J Ullrich
- Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Meena Upadhyaya
- Institute of Cancer Genetics, Cardiff University, Wales, United Kingdom
| | | |
Collapse
|
10
|
Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 2016; 18:624-38. [PMID: 26851632 PMCID: PMC4827037 DOI: 10.1093/neuonc/nov200] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 08/17/2015] [Indexed: 01/08/2023] Open
Abstract
Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN) are tumor-suppressor syndromes. Each syndrome is an orphan disease; however, the tumors that arise within them represent the most common tumors of the nervous system worldwide. Systematic investigation of the pathways impacted by the loss of function of neurofibromin (encoded byNF1) and merlin (encoded byNF2) have led to therapeutic advances for patients with NF1 and NF2. In the syndrome of SWN, the genetic landscape is more complex, with 2 known causative genes (SMARCB1andLZTR1) accounting for up to 50% of familial SWN patients. The understanding of the molecular underpinnings of these syndromes is developing rapidly and offers more therapeutic options for the patients. In addition, common sporadic cancers harbor somatic alterations inNF1(ie, glioblastoma, breast cancer, melanoma),NF2(ie, meningioma, mesothelioma) andSMARCB1(ie, atypical teratoid/rhabdoid tumors) such that advances in management of syndromic tumors may benefit patients both with and without germline mutations. In this review, we discuss the clinical and genetic features of NF1, NF2 and SWN, the therapeutic advances for the tumors that arise within these syndromes and the interaction between these rare tumor syndromes and the common tumors that share these mutations.
Collapse
Affiliation(s)
- Jaishri O Blakeley
- Neurology, Neurosurgery and Oncology, Johns Hopkins University, Baltimore, MD (J.O.B.); Neurology, Harvard Medical School, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA (S.R.P.)
| | - Scott R Plotkin
- Neurology, Neurosurgery and Oncology, Johns Hopkins University, Baltimore, MD (J.O.B.); Neurology, Harvard Medical School, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA (S.R.P.)
| |
Collapse
|
11
|
Sangkhathat S. Current management of pediatric soft tissue sarcomas. World J Clin Pediatr 2015; 4:94-105. [PMID: 26566481 PMCID: PMC4637813 DOI: 10.5409/wjcp.v4.i4.94] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/21/2015] [Accepted: 09/30/2015] [Indexed: 02/06/2023] Open
Abstract
Pediatric soft tissue sarcomas are a group of malignant neoplasms arising within embryonic mesenchymal tissues during the process of differentiation into muscle, fascia and fat. The tumors have a biphasic peak for age of incidence. Rhabdomyosarcoma (RMS) is diagnosed more frequently in younger children, whereas adult-type non-RMS soft tissue sarcoma is predominately observed in adolescents. The latter group comprises a variety of rare tumors for which diagnosis can be difficult and typically requires special studies, including immunohistochemistry and molecular genetic analysis. Current management for the majority of pediatric sarcomas is based on the data from large multi-institutional trials, which has led to great improvements in outcomes over recent decades. Although surgery remains the mainstay of treatment, the curative aim cannot be achieved without adjuvant treatment. Pre-treatment staging and risk classification are of prime importance in selecting an effective treatment protocol. Tumor resectability, the response to induction chemotherapy, and radiation generally determine the risk-group, and these factors are functions of tumor site, size and biology. Surgery provides the best choice of local control of small resectable tumors in a favorable site. Radiation therapy is added when surgery leaves residual disease or there is evidence of regional spread. Chemotherapy aims to reduce the risk of relapse and improve overall survival. In addition, upfront chemotherapy reduces the aggressiveness of the required surgery and helps preserve organ function in a number of cases. Long-term survival in low-risk sarcomas is feasible, and the intensity of treatment can be reduced. In high-risk sarcoma, current research is allowing more effective disease control.
Collapse
|
12
|
Tosun HB, Serbest S, Turk BA, Gumustas SA, Uludag A. Giant malignant peripheral nerve sheath tumor of thigh in an adolescent with neurofibromatosis type 1: a case report. Int Med Case Rep J 2015; 8:267-71. [PMID: 26604833 PMCID: PMC4630200 DOI: 10.2147/imcrj.s92015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are rare sarcomas of children and adolescents, and they are aggressive tumors with a high rate of local recurrence. We present a 15-year-old boy with neurofibromatosis type 1 (NF1), who had a giant MPNST on the right thigh taking into account the available literature. Diagnosis of MPNST may be delayed in NF1 patients due to confusion with a neurofibroma and/or a plexiform neurofibroma. Malignancy should be considered, especially in cases with big masses, with heterogeneous involvement, or in the presence of cysts or necrotic nodules. The aim of surgical treatment is complete surgical excision.
Collapse
Affiliation(s)
- Hacı Bayram Tosun
- Department of Orthopaedics and Traumatology, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey
| | - Sancar Serbest
- Department of Orthopaedics and Traumatology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey
| | - Bilge Aydın Turk
- Department of Pathology, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey
| | - Seyit Ali Gumustas
- Department of Orthopaedics and Traumatology, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey
| | - Abuzer Uludag
- Department of Orthopaedics and Traumatology, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey
| |
Collapse
|